NEW YORK, Jan 19 – Third Wave Technologies is planning to test the IPO waters with a roadshow that is scheduled to begin next week, a company spokeswoman said Friday.

The company is hoping to sell 8.5 million shares at $11 - $13 a share in an offering that could raise as much as $110 million for the Madison, Wis.-based maker of SNP analysis technologies.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.